Introduction
Proof of principle (POP) trials are used early in drug development, typically after phase 1 or early in phase 2, and aim to give an early read out of potential efficacy. In the area of epilepsy, biomarkers are not readily available and mechanisms of action may not be fully elucidated for some classes of drugs. Thus, POP trials have significant potential in anti-epileptic drug (AED) development by providing early indicators of efficacy, improving decision-making and potentially reducing the cost of Phase 2/3 failures.
POP trials for epilepsy include inter-ictal discharges, transmagnetic cranial stimulation or photosensitive epilepsy, of which the first two have been associated with variable responses or providing limited data for the effects of AEDs. 1 Photosensitive POP trials can be a reliable early indicator of pharmacodynamic activity for a number of novel AEDs. [2] [3] [4] [5] In these trials, photosensitive epileptic patients are exposed to intermittent photic stimulation and the provocation of paroxysmal discharges is monitored. The outcome measured is the number of standard visual stimulation frequencies to which the patient is sensitive, and response can generally be classified as complete abolishment of sensitivity, partial or none. Since photosensitive POP trials have already been shown qualitatively to be an early indicator of pharmacodynamic activity, the aim of this research was to take a step further to quantify the predictive capabilities of photosensitive POP trials, in order to better characterise the utility of such trials in epilepsy drug development. This was done through a survey of current literature reporting results on photosensitive POP trials.
Materials and methods
A literature search was undertaken in PubMed (http:// www.ncbi.nlm.nih.gov/pubmed/) using four different combinations of keywords. The first search used ''photosensitive'' and ''epilepsy'', and the second replaced the keyword ''photosensitive'' with ''photosensitivity''. This was then repeated for the third and fourth searches by adding the term ''model''. Search results were sorted by recently added articles and all e-publications ahead of print were separately identified prior to the addition of filters of ''clinical trial'' and/or ''humans'' to the results. Articles describing photosensitive POP trials using a single dose of AED were included, whilst articles describing clinical trials for non-drug treatment or chronic treatment of photosensitive epilepsy with AEDs were excluded.
Minimally efficacious doses (MEDs) for treatment of epilepsy (partial, generalised or both) for approved AEDs described in the POP trials were obtained from the respective drug labels. For nonapproved AEDs, a search was conducted in PubMed (http:// www.ncbi.nlm.nih.gov/pubmed/) using the drug name as keyword and limited to clinical trials. MEDs were determined from doubleblind, placebo controlled trials in partial or generalised epilepsy where significance from placebo was observed. Where more than one trial was available for a particular drug, the average across the lowest efficacious doses in each trial was obtained. In the POP trials, efficacious doses were defined as dose levels in which 50-100% of patients had a positive response (ED 50-100 ), where a response was considered to be either a complete abolishment or a significant partial decrease in sensitivity to standard visual frequencies. No attempt was made to distinguish between these two types of positive responses since small numbers of patients (majority of trials had 4-6 patients per dose level, range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] were typically tested at each dose level.
For each AED, the ratio of MED to ED 50-100 was calculated when both values were available, since efficacy data was not available for all drugs used in photosensitive POP trials. The ratios were described by summary statistics. No weighting factor was included for study size and/or quality since the conduct of most of these trials were similar using small numbers of patients.
Results
In total, ten articles were identified that fit the inclusion criteria. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The results of the literature search are described in Table 1 . Of the ten, eight described positive results only, one described an unexpected increase in photosensitive epilepsy when patients were given Org 6370, 6 and another described mixed results with two marketed AEDS (carbamazepine and levetiracetam). 10 These ten articles described the use of a total of 17 drugs in photosensitive epilepsy POP trials, however efficacy data (MED) was only found for 13 drugs, since some drugs had not undergone phase 2/3 trials or the trial results had not been reported at the time of conducting the search. Of the 13 AEDs, six were indicated in partial seizures, three in generalised seizures and three in both types. The doses investigated in the POP trials were either close to, or encompassed the MED for epilepsy. The results show that across the AEDs, the average ratio of MED to ED 50-100 was 0.95 (95% CI 0.60-1.30) with all ratios contained within 2-fold. The difference in MED to ED 50-100 ratios between partial epilepsy (0.82, 95% CI 0.46-1.18) was not significantly different from that of generalised epilepsy (1.08, 95% CI 0.60-1.56) (p = 0.51). The ratios of MED to ED 50-100 for each AED are reported in Table 2 . 
Discussion
This literature survey investigated the utility of photosensitive POP trials for quantitatively predicting efficacy in partial or generalised epilepsy. This was achieved by comparing the efficacious doses in photosensitive POP trials versus the efficacious doses of marketed AEDs or those reported in latestage clinical trials for AEDs currently under investigation. The results showed that single dose photosensitive POP trials can be a reliable quantitative indicator of efficacy in epilepsy, with the average ratio of epilepsy MEDs to doses associated with 50-100% responses in the photosensitive POP trials of 0.95. Where individual ratios were less than 1, the ED 50-100 was captured in the usual maintenance dose range for marketed AEDs. This is a particularly encouraging result for drug development of AEDs, since photosensitive POP trials use only a single dose and thus can be conducted immediately after a single dose ascending study. The probability of technical success can be increased early in drug development, with the results from the POP trial not only indicating potential efficacy in epilepsy, but also providing information for dose selection in phase 2 and phase 3 epilepsy trials. It may also be used as a tool to screen drugs for new indications in epilepsy, as in the case of pitolisant, a histamine-3 receptor (H3R) antagonist, where drug development efforts have been initially focused on narcolepsy, Parkinson's disease and obstructive sleep apnea. 7 Of the total of 17 drugs identified in the literature survey, only two drugs were reported to have failed in the photosensitive POP trials. Carbamazepine showed positive results in an earlier study, 5 but the findings could not be replicated in a recent study at the same dose. 10 The authors postulated that drug concentration levels for carbamazepine were not available from the earlier trial and may have explained the differences between the two studies. The other reported drug that failed in the photosensitive POP trials was Org 6370, despite having shown efficacy in animal epilepsy models. 6 Information on AED efficacy in humans for this drug was not available, therefore it was not possible to assess if this was a true or false negative. One of the major caveats of this analysis is that only true positive cases (and a mixed case with carbamazepine) have been shown. The omission of false positive or false negative cases does not indicate the lack of such cases, but rather these are less likely to be reported. 2 Therefore, it is important to acknowledge that a positive photosensitive POP trial will not necessarily guarantee future success in an epilepsy efficacy trial and vice versa. Other caveats that need to be taken into consideration for interpretation of the results of this literature survey include the small numbers of subjects (usually N = 4-6 per cohort) who are often co-medicated but stable on other AEDs. Although blood samples were taken to ensure the drug levels of the co-medications were not altered on administration of the investigative drug, a pharmacodynamic interaction (e.g. synergism) may still be present. Some AEDs identified in this literature survey may no longer be prescribed or frequently used due to efficacy or toxicity profiles which have since emerged. This is to be expected since these tend to be older drugs with a higher likelihood of being discarded in favour of newer ones with better safety-efficacy balance. The aim of the current literature survey was to use photosensitive trials POP trials to predict efficacy rather than safety, hence it was deemed advantageous to look across a wide range of drugs that have shown some degree of efficacy in the treatment of epilepsy, especially since the disease area may still not be well understood. Approximately 70% of photosensitive patients with a history of epilepsy have generalised epilepsy versus 30% with partial epilepsy. 8 Thus, one could postulate that results from photosensitive POP trials may be more indicative of efficacy in generalised rather than partial epilepsy. Whilst the biology of the ability of the photosensitivity model to predict efficacy in non-photosensitive epilepsy is not well understood and may be overestimated because of a positive publication bias, it would appear that a positive effect in the POP trials strongly suggests efficacy in other epilepsy syndromes. Of the AEDs presented in this paper, nine are indicated in partial epilepsy and six are indicated for generalised epilepsy but there was no significant difference in MED:ED 50-100 ratios between drugs used for treatment of partial and generalised epilepsy. This would suggest that results of photosensitive POP trials are equally applicable in prediction of drug efficacy in both partial and generalised seizures. Clinicians appreciate that many non-photic epilepsies have varied triggers, such as stress, lack of sleep or specific sensory stimuli, however the issue with these triggers is their lack of reproducibility. The photosensitivity model's success is lies in its reproducibility to trigger rather than the specificity of the epileptic circuitry that exists for these particular patients or even some of the similar photosensitive animal models. We would hypothesize that drugs that are highly specific, for a type of circuit or type of propagation, which exists beyond a photosensitive model, could generate a false negative signal.
In conclusion, photosensitive POP trials are a useful tool to quantitatively predict efficacy in epilepsy. Doses corresponding to 50-100% response in these POP trials were found to be within 2-fold to the minimally efficacious doses used in partial or general epilepsy. Thus, single dose photosensitive POP trials can be useful as early and informative indicators in AED discovery and development, particularly in aiding dose selection in phase 2 and 3 epilepsy trials.
